Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACSTNASDAQ:BHSTNASDAQ:KRRONASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsBHSTBioHarvest Sciences$6.90+1.2%$6.66$4.66▼$7.86$113.33M0.658,895 shs1,386 shsKRROKorro Bio$12.90-1.5%$14.18$10.29▼$98.00$121.13M2.43106,594 shs33,300 shsTHTXTheratechnologies$3.13+32.6%$2.60$1.12▼$3.20$143.92M0.55860,785 shs10.56 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%-7.72%+7.24%BHSTBioHarvest Sciences+1.17%+1.47%+4.07%+24.55%+689,999,900.00%KRROKorro Bio-1.45%+4.54%+8.13%-10.29%-66.34%THTXTheratechnologies+32.63%+33.76%+19.92%+111.49%+131.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti PharmaN/AN/AN/AN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/AKRROKorro Bio2.4037 of 5 stars3.63.00.00.02.10.00.6THTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsideBHSTBioHarvest Sciences 3.00Buy$13.6798.07% UpsideKRROKorro Bio 3.29Buy$102.43694.02% UpsideTHTXTheratechnologies 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest ACST, THTX, BHST, and KRRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/13/2025KRROKorro BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.005/8/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$115.00 ➝ $100.005/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/29/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.004/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.004/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/8/2025BHSTBioHarvest SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/ABHSTBioHarvest Sciences$27.70M4.09N/AN/A$0.08 per share86.25KRROKorro Bio$2.27M53.36N/AN/A$17.12 per share0.75THTXTheratechnologies$85.87M1.68N/AN/A($0.55) per share-5.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/ABHSTBioHarvest Sciences-$12.91M-$0.50N/AN/AN/A-31.30%-307.04%-33.21%8/14/2025 (Estimated)KRROKorro Bio-$83.58M-$9.44N/AN/AN/AN/A-51.64%-37.94%8/12/2025 (Estimated)THTXTheratechnologies-$8.31M-$0.08N/A44.71N/A-4.18%N/A-0.37%7/9/2025 (Estimated)Latest ACST, THTX, BHST, and KRRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million5/7/2025Q1 2025KRROKorro Bio-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86BHSTBioHarvest SciencesN/A0.510.30KRROKorro BioN/A9.419.41THTXTheratechnologiesN/A1.080.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%BHSTBioHarvest SciencesN/AKRROKorro Bio13.18%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%BHSTBioHarvest SciencesN/AKRROKorro Bio4.60%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/AKRROKorro Bio709.39 million8.96 millionNo DataTHTXTheratechnologies14045.98 millionN/AOptionableACST, THTX, BHST, and KRRO HeadlinesRecent News About These CompaniesFuture Pak to buy Theratechnologies for $254 millionJuly 4 at 10:42 AM | thepharmaletter.comTTheratechnologies Stock (NASDAQ:THTX), Insider Trading ActivityJuly 3 at 12:41 AM | benzinga.comTheratechnologies Inc. (THTX) - Yahoo FinanceJuly 3 at 12:41 AM | finance.yahoo.comTheratechnologies Stock Short Interest Report | NASDAQ:THTX - BenzingaJuly 3 at 12:41 AM | benzinga.comTheratechnologies shareholders should take the deal, Research Capital saysJuly 3 at 7:40 PM | cantechletter.comCTheratechnologies to be bought by CB Biotechnology for $254MJuly 3 at 7:40 PM | msn.comTheratechnologies to Announce Second Quarter 2025 Financial ResultsJuly 3 at 5:30 PM | globenewswire.comTheratechnologies' (THTX) Hold Rating Reaffirmed at Jones TradingJuly 3 at 8:27 AM | marketbeat.comTheratechnologies to be Acquired by Future Pak AffiliateJuly 2 at 11:11 PM | tipranks.comTheratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future PakJuly 2 at 11:09 PM | finance.yahoo.comTheratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future PakJuly 2 at 10:11 PM | globenewswire.comTheratechnologies Reports on its Annual Meeting of ShareholdersMay 29, 2025 | globenewswire.comTheratechnologies announces annual shareholder meetingMay 4, 2025 | uk.investing.comTheratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIVMay 2, 2025 | globenewswire.comTheratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 OfferApril 18, 2025 | seekingalpha.comIs Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comTheratechnologies to further evaluate potential sale of the companyApril 16, 2025 | markets.businessinsider.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | financialpost.comFTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | globenewswire.comTheratechnologies Engages in Exclusive Acquisition TalksApril 15, 2025 | tipranks.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACST, THTX, BHST, and KRRO Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.BioHarvest Sciences NASDAQ:BHST$6.90 +0.08 (+1.17%) As of 07/3/2025 12:59 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Korro Bio NASDAQ:KRRO$12.90 -0.19 (-1.45%) As of 07/3/2025 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Theratechnologies NASDAQ:THTX$3.13 +0.77 (+32.63%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$3.16 +0.02 (+0.80%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
